Literature DB >> 2204172

Experimental studies of chemosensitivity testing of urothelial cancer grown in nude mice.

A P Kyriazis1, A A Kryiazis, A Yagoda.   

Abstract

The present study provides information relevant to a number of variables which may influence response to treatment of nude mouse-grown human urothelial cancer. A number of xenotransplanted tumors were exposed to selected treatments at different transplant generations, and at various dose levels and treatment schedules. It was observed that nude mouse-grown tumors were characterized by consistency, reproducibility and biological stability not affected by the transplant generation at which they were examined. Treatment related dose response curves were steep, the sharpness of the curves depending on the degree of tumor sensitivity. Best therapeutic results were obtained at the maximum tolerated dose of cytotoxic agents under study and of importance, a 20% to 40% dose reduction with the same treatment schedule resulted in little or no activity. In addition, treatment schedule, timing and sequence of treatments and to a certain degree, tumor grade were important variables which could influence tumor response. The nude mouse-human tumor system provides important preclinical guidelines on dose, schedule, sequence and timing of treatments and can assist in designing more efficient clinical trials.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2204172     DOI: 10.1007/bf00295848

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  21 in total

1.  Heterotransplantation of a human malignant tumour to "Nude" mice.

Authors:  J Rygaard; C O Povlsen
Journal:  Acta Pathol Microbiol Scand       Date:  1969

2.  Response to ionizing radiation of human bladder transitional cell carcinomas grown in the nude mouse.

Authors:  A P Kyriazis; A Yagoda; A A Kyriazis; J G Kereiakes; W B McCombs
Journal:  Exp Cell Biol       Date:  1985

3.  Experimental studies and phase II trial of bisantrene in advanced urothelial malignancies.

Authors:  H I Scher; T Ahmed; A Yagoda; A P Kyriazis; R C Watson
Journal:  Cancer Invest       Date:  1985       Impact factor: 2.176

4.  Plasma levels and urinary excretion of filterable platinum species following bolus injection and iv infusion of cis-dichlorodiammineplatinum(II) in man.

Authors:  T F Patton; K J Himmelstein; R Belt; S J Bannister; L A Sternson; A J Repta
Journal:  Cancer Treat Rep       Date:  1978-09

5.  Experimental studies on the response of nude mouse-grown human urothelial cancer to high dose of 1-beta-D-arabinofuranosylcytosine.

Authors:  A P Kyriazis; A Yagoda; A A Kyriazis; G L Royer
Journal:  Cancer Invest       Date:  1988       Impact factor: 2.176

6.  Establishment and characterization of human pancreatic adenocarcinoma cell line SW-1990 in tissue culture and the nude mouse.

Authors:  A P Kyriazis; W B McCombs; A A Sandberg; A A Kyriazis; N H Sloane; R Lepera
Journal:  Cancer Res       Date:  1983-09       Impact factor: 12.701

7.  Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II.

Authors:  A H Calvert; S J Harland; D R Newell; Z H Siddik; A C Jones; T J McElwain; S Raju; E Wiltshaw; I E Smith; J M Baker; M J Peckham; K R Harrap
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

8.  Histopathologic evaluation of response to treatment of human tumors grown in the nude mouse.

Authors:  A A Kyriazis; A P Kyriazis; J G Kereiakes; M S Soloway; W B McCombs
Journal:  Exp Cell Biol       Date:  1983

9.  Morphological, biological, and biochemical characteristics of human bladder transitional cell carcinomas grown in tissue culture and in nude mice.

Authors:  A A Kyriazis; A P Kyriazis; W B McCombs; W D Peterson
Journal:  Cancer Res       Date:  1984-09       Impact factor: 12.701

10.  Time dependence of the radiation-modifying effect of cis-diamminedichloroplatinum II (cisplatin, DDP) on human urothelial cancer grown in nude mice.

Authors:  A P Kyriazis; A A Kyriazis; A Yagoda
Journal:  Cancer Invest       Date:  1986       Impact factor: 2.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.